Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SHOULSON, I.
Right arrow Articles by CHASE, T. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SHOULSON, I.
Right arrow Articles by CHASE, T. N.
NEUROLOGY 1975;25:1144
© 1975 American Academy of Neurology

On-off response

Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients

IRA SHOULSON, M.D., GEORGE A. GLAUBIGER, M.D., Ph.D. and THOMAS N. CHASE, M.D.

Laboratory of Neuropharmacology, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health.

Seven parkinsonian patients who had severe on-off effects during chronic treatment with levodopa were studied. Marked swings in plasma dopa levels as well as in motor function followed each oral dose of levodopa. A constant intravenous infusion of levodopa resulted in stable plasma dopa concentrations and virtual disappearance of motor fluctuations. Notwithstanding steady plasma dopa levels, an abrupt decline in the antiparkinsonian response to levodopa attended postural tilting or cold pressor stimulation. Although these maneuvers were accompanied by a significant rise in plasma norepinephrine, the intravenous infusion of this catecholamine failed to influence the effect of levodopa on parkinsonian signs. The results suggest that central noradrenergic mechanisms as well as alterations in circulating dopa may contribute to the on-off response to levodopa.

Received for publication May 21, 1975.

Dr. Shoulson's present address is Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.




This article has been cited by other articles:


Home page
 NeurologyHome page
R. F. Pfeiffer
A promising new technology for Parkinson's disease
Neurology, July 26, 2005; 65(2_suppl_1): S6 - S10.
[Full Text]

Home page
 BrainHome page
R. de la Fuente-Fernandez, M. Schulzer, E. Mak, D. B. Calne, and A. J. Stoessl
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model
Brain, April 1, 2004; 127(4): 888 - 899.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. A. LeWitt and D. Nyholm
New developments in levodopa therapy
Neurology, January 13, 2004; 62(90011): S9 - 16.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
L. M. Shulman
Levodopa Toxicity in Parkinson Disease: Reality or Myth?: Reality--Practice Patterns Should Change
Arch Neurol, March 1, 2000; 57(3): 406 - 408.
[Full Text] [PDF]

Home page
 J. Neurosci.Home page
W. Y. Lee, J. W. Chang, N. L. Nemeth, and U. J. Kang
Vesicular Monoamine Transporter-2 and Aromatic L-Amino Acid Decarboxylase Enhance Dopamine Delivery after L-3,4-Dihydroxyphenylalanine Administration in Parkinsonian Rats
J. Neurosci., April 15, 1999; 19(8): 3266 - 3274.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. E. Ahlskog, M. D. Muenter, D. M. Maraganore, J. Y. Matsumoto, A. Lieberman, K. F. Wright, and K. Wheeler
Fluctuating Parkinson's Disease: Treatment With the Eong-Acting Dopamine Agonist Cabergoline
Arch Neurol, December 1, 1994; 51(12): 1236 - 1241.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
P. J. Karstaedt, J. H. Pincus, and S. S. Coughlin
Standard and Controlled-Release Levodopa/Carbidopa in Patients With Fluctuating Parkinson's Disease on a Protein Redistribution Diet: A Preliminary Report
Arch Neurol, April 1, 1991; 48(4): 402 - 405.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. T. Hutton, J. L. Morris, G. C. Roman, S. C. Imke, and J. W. Elias
Treatment of Chronic Parkinson's Disease With Controlled-Release Carbidopa/Levodopa
Arch Neurol, August 1, 1988; 45(8): 861 - 864.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. T. Hutton, J. W. Albrecht, G. C. Roman, and M. T. Kopetzky
Prolonged Serum Levodopa Levels With Controlled-Release Carbidopa-Levodopa in the Treatment of Parkinson's Disease
Arch Neurol, January 1, 1988; 45(1): 55 - 57.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. Kurlan
Dietary Therapy for Motor Fluctuations in Parkinson's Disease
Arch Neurol, November 1, 1987; 44(11): 1119 - 1121.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. L. Juncos, G. Fabbrini, M. M. Mouradian, and T. N. Chase
Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations
Arch Neurol, October 1, 1987; 44(10): 1010 - 1012.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. H. Pincus and K. Barry
Influence of Dietary Protein on Motor Fluctuations in Parkinson's Disease
Arch Neurol, March 1, 1987; 44(3): 270 - 272.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
E. Melamed
Initiation of Levodopa Therapy in Parkinsonian Patients Should Be Delayed Until the Advanced Stages of the Disease
Arch Neurol, April 1, 1986; 43(4): 402 - 405.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
A. J. Rosin, D. Devereux, N. Eng, and D. B. Calne
Parkinsonism With 'On-Off' Phenomena: Intravenous Treatment With Levodopa After Major Abdominal Surgery
Arch Neurol, January 1, 1979; 36(1): 32 - 34.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1975 by AAN Enterprises, Inc.